A5005289841- Bone health and osteoporosis research
- Hip and Femur Fractures
- Bone health and treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Health Systems, Economic Evaluations, Quality of Life
- Lipoproteins and Cardiovascular Health
- Bone Metabolism and Diseases
- Orthopaedic implants and arthroplasty
- Digital Radiography and Breast Imaging
- Breast Cancer Treatment Studies
- Medical Imaging Techniques and Applications
- Pelvic and Acetabular Injuries
- Bone fractures and treatments
- Estrogen and related hormone effects
- Hip disorders and treatments
Radius Health (United States)
2020-2025
Pear Therapeutics (United States)
2023
University of Maryland Upper Chesapeake Health
2023
Eli Lilly (United States)
2010
Anabolic therapies, recommended for patients at very high fracture risk, are administered subcutaneously (SC). The objective of this study was to evaluate the efficacy and safety abaloparatide microstructured transdermal system (abaloparatide-sMTS) as an alternative SC formulation. This phase 3, noninferiority (NCT04064411) randomly assigned postmenopausal women with osteoporosis (N = 511) 1:1 open-label daily via abaloparatide-sMTS or injection 12 months. primary comparison between...
Abstract Background Osteoporotic-related fractures represent an increasing burden to patients, health care systems and society. Aims This study estimated cost-effectiveness of sequential treatment with abaloparatide (ABL) followed by alendronate (ALN) compared relevant alternative strategies in US men women aged 50 80 years at very high fracture risk (bone mineral density T-score ≤ − 2.5 a recent fracture). Methods A lifetime Markov-based microsimulation model was used estimate healthcare...
Abstract The goal of treatment for women at high risk fracture who have a T-score ≤ −2.5 is to mitigate by achieving T-scores least above −2.5. In the ACTIVE trial, 2463 with osteoporosis aged 49 86 yr were treated 18 mo abaloparatide (80 μg), teriparatide (20 or placebo. Eligible from and placebo groups then weekly 70 mg alendronate 2 additional years in ACTIVExtend. This post hoc analysis ACTIVExtend included baseline total hip (TH) lumbar spine (LS) − 2.5. Logistic regression was used...
Introduction: Lack of consideration for risk-based assessments that inform osteoporosis treatment decisions may contribute to disease burden. In this study, we examined the prevalence patients at very high risk fracture and evaluated real-world practices these patients. Methods: This retrospective observational cohort study used data linked commercial Medicare medical claims from Symphony Health PatientSource. Patients 50 years older with (determined by presence a diagnosis code) according...
Abaloparatide (ABL) significantly increases bone mineral density in men with osteoporosis similar to what was reported postmenopausal women osteoporosis. The cost effectiveness of sequential treatment ABL followed by alendronate (ALN) at high fracture risk compared relevant alternative treatments. A Markov-based microsimulation model based on a lifetime US healthcare decision maker perspective developed evaluate the (expressed US$2021) per quality-adjusted life-years (QALYs) gained ABL/ALN....
Abstract Osteoporosis in men is an underappreciated public health issue, accounting for approximately 30% of the societal burden osteoporosis. Although prevalence osteoporosis lower, fracture-related morbidity and mortality rates exceed those women. Abaloparatide a synthetic, 34-amino acid peptide with homology to human parathyroid hormone-related protein (PTHrP), which favors bone formation by selective activation PTH receptor type 1. In Treatment Men With (ATOM; NCT03512262) trial, 228...
ABSTRACT Abaloparatide significantly increased bone mineral density (BMD) in women with postmenopausal osteoporosis and decreased risk of vertebral, nonvertebral, clinical fractures compared placebo. The for the Treatment Men Osteoporosis (ATOM; NCT03512262) study evaluated efficacy safety abaloparatide placebo men. Eligible men aged 40 to 85 years were randomized 2:1 daily subcutaneous injections 80 μg or 12 months. primary endpoint was change from baseline lumbar spine BMD. Key secondary...
Objectives: Treatment initiation and persistence after a fragility fracture are critical to reduce the risk of subsequent fractures. The authors evaluated osteoporosis management outcomes index fracture. Methods: This retrospective cohort study used real-world data for patients (≥50 years), including pharmacy claims linked commercial Medicare medical from Symphony Health Patient Source. Osteoporosis was at least 12 months first case-qualifying during identification period continued until...
Review of medical records from 173 women with osteoporosis who received abaloparatide treatment revealed that 96.0% had at least one visit for management and 55.5% medication support group access. The most common reasons discontinuing were financial (31.2%) tolerability (22.8%). Most patients (64.8%) completed as prescribed.
To evaluate the effects of 6 and 18 months abaloparatide (ABL) compared with placebo (PBO) on bone mineral density (BMD) in acetabular regions postmenopausal women osteoporosis (OP). Acetabular loss, as may occur OP, increases risk fragility fractures a . In total hip arthroplasty (THA), low BMD adversely affects primary stability, osseointegration, migration cups. c ABL is an osteoanabolic agent for treatment men OP at high fracture. Effects are unknown. Hip DXA scans were obtained...
Introduction There are limited data on the management of bone health, including mineral density (BMD) evaluation and osteoporosis (OP) treatment, in patients undergoing elective orthopaedic surgeries. Methods This was a retrospective cohort study using administrative claims from Symphony Health, PatientSource for aged ≥50 years with documented kyphoplasty/vertebroplasty (KP/VP), total knee arthroplasty (TKA), hip (THA). Risk stratification to identify at very high risk fracture (VHRFx) based...
Abstract Disclosure: M. Hiligsmann: Grant Recipient; Self; Radius Health, Inc. S. Silverman: Consulting Fee; Amgen Inc, A.J. Singer: Agnovos, UCB. Speaker; L. Pearman: Employee; Stock Owner; Y. Wang: J.N. Caminis: J. Reginster: Advisory Board Member; Pierre Fabre. IBSA-Genevrier, Mylan, Teva Pharmaceutical Industries Ltd. CNIEL, Dairy Research Council, Background: Cost-effectiveness analyses are becoming increasingly important for efficiency in healthcare resource allocation. This study aims...